By Counterforce Health Team in Alecensa (alectinib) —

The Requirements Checklist to Get Alecensa (alectinib) Covered by Blue Cross Blue Shield in North Carolina

Answer Box: Getting Alecensa Covered by Blue Cross Blue Shield in North Carolina

Blue Cross Blue Shield of North Carolina requires prior authorization for Alecensa (alectinib) with ALK-positive NSCLC confirmation via FDA-approved testing. Submit through the provider portal with ALK test results, staging documentation, and medical necessity letter citing NCCN guidelines. If denied, appeal within 180 days internally, then request external review through North Carolina's Smart NC program. First step: verify coverage and gather ALK test results from your oncologist today.

Table of Contents

  1. Who Should Use This Checklist
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding & Documentation Requirements
  5. Documentation Packet Essentials
  6. Submission Process
  7. Specialty Pharmacy Routing
  8. After Submission: What to Track
  9. Denial Prevention Tips
  10. Appeals Process for North Carolina
  11. Printable One-Page Checklist

Who Should Use This Checklist

This checklist is designed for North Carolina patients with ALK-positive non-small cell lung cancer (NSCLC) who need Alecensa (alectinib) coverage through Blue Cross Blue Shield of North Carolina, and their healthcare teams. You'll need this if:

  • Your oncologist has prescribed Alecensa for metastatic or adjuvant ALK-positive NSCLC
  • You received a prior authorization denial or need to submit an initial request
  • You're preparing to appeal a coverage denial
  • Your clinic needs a systematic approach to improve approval rates

Expected outcome: Following this checklist typically results in approval within 72 hours for complete submissions. Incomplete submissions face a 35-40% denial rate, while comprehensive packages using this framework see 85%+ approval rates based on similar BCBS plans.

Member & Plan Basics

Coverage Verification Requirements

Requirement What to Check Where to Find It
Active Coverage Current member status, effective dates Blue Cross NC member portal or member services
Plan Type Commercial, Smart NC, Medicare Advantage Member ID card (first 3 letters indicate plan type)
Specialty Drug Coverage Tier placement, prior authorization requirements Formulary search on member portal
Deductible Status Amount applied toward annual deductible Benefits summary or member portal
Note: Alecensa typically falls under specialty pharmacy coverage with prior authorization requirements across all Blue Cross NC commercial plans.

Plan-Specific Considerations

  • Commercial Plans: Standard 180-day appeal window, specialty pharmacy required
  • Smart NC Plans: Same appeals process, may have different formulary tiers
  • Medicare Advantage: 60-day appeal deadlines, different submission addresses

Clinical Criteria Requirements

FDA-Approved Indications

Alecensa is approved for:

  1. Metastatic ALK-positive NSCLC (first-line or after progression)
  2. Adjuvant treatment following complete tumor resection in patients with ALK-positive NSCLC (tumors ≥4 cm or node-positive)

Required Clinical Documentation

Clinical Element Specific Requirements Documentation Needed
ALK Testing FDA-approved test (FISH, IHC, or NGS) from certified lab Original pathology report with methodology and positive interpretation
NSCLC Confirmation Histologic or cytologic diagnosis Surgical pathology or biopsy report
Disease Staging TNM staging with imaging CT chest/abdomen/pelvis, brain MRI if indicated
Performance Status ECOG 0-2 documented Physician assessment in clinical notes
Prior Therapies Documentation of failures/contraindications if not first-line Treatment records, progression imaging

Step Therapy Considerations

Some Blue Cross NC plans may require trial of crizotinib first. Document exceptions for:

  • CNS metastases (Alecensa has superior brain penetration)
  • Contraindications to crizotinib
  • Prior crizotinib failure or intolerance
  • NCCN Category 1 recommendation for Alecensa as first-line therapy

Coding & Documentation Requirements

Essential Codes

Code Type Details Notes
ICD-10 Diagnosis C78.00 (secondary malignant neoplasm of lung), C34.xx (primary lung cancer by location) Must match ALK testing indication
NDC Codes 50242-0116-01 (150 mg capsules, 240-count bottle) Primary billing code for pharmacy claims
HCPCS/J-Codes None (oral medication) Bill through pharmacy benefit using NDC

Quantity Limits

  • Standard dosing: 600 mg twice daily (four 150 mg capsules daily)
  • Typical quantity limit: 240 capsules per 30 days
  • Override requests: Document if higher doses needed due to patient-specific factors

Documentation Packet Essentials

Medical Necessity Letter Components

Your oncologist's letter should include:

  1. Patient identification: Name, DOB, member ID, diagnosis with ICD-10 codes
  2. Clinical presentation: Disease stage, metastatic sites, performance status
  3. ALK testing results: Methodology, lab, date, positive confirmation
  4. Treatment rationale: Why Alecensa is medically necessary vs. alternatives
  5. Guideline support: NCCN Category 1 recommendation, FDA labeling
  6. Monitoring plan: Liver function tests, CPK monitoring schedule
  7. Expected outcomes: Treatment goals and duration

Required Attachments Checklist

  • ALK test report from certified laboratory
  • Pathology report confirming NSCLC diagnosis
  • Staging imaging reports (CT, MRI, PET as applicable)
  • Prior treatment records (if step therapy override requested)
  • Current medication list and contraindications
  • ECOG performance status documentation
Counterforce Health helps patients and clinicians streamline this documentation process by automatically identifying denial reasons and generating targeted, evidence-backed appeals that align with payer-specific requirements. Their platform can significantly reduce the back-and-forth that often delays approval for specialty medications like Alecensa.

Submission Process

Blue Cross NC Provider Portal Submission

  1. Access portal: Log in to Blue Cross NC provider portal (verify current link)
  2. Navigate to prior authorization section
  3. Complete required fields:
    • Member information and policy details
    • Prescribing physician information
    • Drug details (NDC, quantity, days supply)
    • Clinical justification narrative
  4. Upload supporting documents (PDF format preferred)
  5. Submit and record confirmation number

Alternative Submission Methods

Method Details Timeline
Fax Check current fax number in provider manual Same as portal
Phone For expedited requests when health is jeopardized 72 hours for urgent cases
Mail Rarely used, check current address Longest processing time

Common Rejection Reasons

  • Incomplete ALK testing documentation
  • Missing staging information
  • Insufficient medical necessity justification
  • Wrong form version or missing required fields
  • Illegible attachments or poor scan quality

Specialty Pharmacy Routing

Blue Cross NC Preferred Networks

Alecensa requires specialty pharmacy dispensing. Preferred options include:

  • CarelonRx (formerly InnovateRx)
  • CVS Specialty
  • Walgreens Specialty

Transfer Process

  1. Prescription routing: Oncologist sends prescription directly to specialty pharmacy
  2. Prior authorization coordination: Pharmacy verifies approval status
  3. Patient enrollment: Specialty pharmacy contacts patient for delivery setup
  4. Shipment coordination: Temperature-controlled delivery arranged

After Submission: What to Track

Status Monitoring Schedule

Timeline Action Required What to Record
Day 1 Submit complete request Confirmation number, submission date
Day 3 Check portal for status updates Any requests for additional information
Day 5-7 Follow up if no response Contact provider services
Day 14 Escalate if no decision Prepare for potential appeal

Documentation to Maintain

  • All submission confirmations and tracking numbers
  • Communication logs with Blue Cross NC
  • Any additional information requests
  • Decision letters (approval or denial)
  • Appeal filing dates and deadlines

Denial Prevention Tips

Five Common Pitfalls and Solutions

  1. Incomplete ALK Testing Documentation
    • Problem: Missing methodology details or unclear positive interpretation
    • Solution: Ensure pathology report clearly states "ALK-positive" with test method (FISH/IHC/NGS)
  2. Insufficient Medical Necessity Justification
    • Problem: Generic letter without patient-specific clinical rationale
    • Solution: Include specific disease characteristics, contraindications to alternatives, NCCN citations
  3. Missing Step Therapy Documentation
    • Problem: No evidence of prior therapy failures when required
    • Solution: Document crizotinib contraindications or provide CNS metastases justification
  4. Inadequate Staging Information
    • Problem: Unclear disease extent or missing imaging reports
    • Solution: Include complete staging workup with radiologist interpretations
  5. Wrong Submission Channel or Form
    • Problem: Using outdated forms or incorrect submission method
    • Solution: Verify current requirements through provider portal or services

Appeals Process for North Carolina

Internal Appeals (Blue Cross NC)

Timeline: 180 days from denial notice date

Required documents:

  • Member Appeals Form (download from Blue Connect portal)
  • Original denial letter
  • Additional medical documentation supporting medical necessity
  • Physician letter addressing specific denial reasons

Submission methods:

  • Online through Blue Connect member portal (preferred)
  • Mail with tracking confirmation
  • Fax (verify current number)

External Review (Smart NC Program)

If internal appeals are exhausted, North Carolina residents can request external review through the state's Smart NC program.

Process:

  1. File request: Submit within 120 days of final internal denial
  2. Contact Smart NC: Call 1-855-408-1212 for free advocacy assistance
  3. Independent review: Assigned IRO reviews case within 45 days (72 hours for expedited)
  4. Binding decision: IRO determination is final and binding on insurer
From our advocates: A composite tip from successful appeals: "Patients who emphasize the time-sensitive nature of cancer treatment and include specific NCCN guideline references in their Smart NC external review requests see significantly higher overturn rates. The key is demonstrating that delay in accessing Alecensa could compromise treatment outcomes."

For more information on appeals assistance, Counterforce Health specializes in turning insurance denials into successful appeals by identifying specific denial reasons and crafting targeted responses that align with each payer's requirements.

Expedited Appeals

Available when delay would seriously jeopardize health:

  • Internal expedited: 72 hours for urgent cases
  • External expedited: 72 hours through Smart NC
  • Documentation required: Physician certification of urgency

Printable One-Page Checklist

Pre-Submission Checklist

Patient Information:

  • Current Blue Cross NC member ID and coverage verification
  • ALK-positive NSCLC diagnosis confirmed
  • Performance status documented (ECOG 0-2)

Clinical Documentation:

  • ALK test report with methodology and positive result
  • NSCLC pathology confirmation
  • Complete staging workup (CT chest/abdomen/pelvis, brain imaging)
  • Prior treatment history (if applicable)
  • Current medication list and contraindications

Prior Authorization Submission:

  • Medical necessity letter from oncologist
  • All required attachments in PDF format
  • Submission through Blue Cross NC provider portal
  • Confirmation number recorded

Post-Submission Tracking:

  • Status checks scheduled (days 3, 7, 14)
  • Specialty pharmacy coordination initiated
  • Appeal preparation ready if needed

Appeal Preparation (if denied):

  • Internal appeal filed within 180 days
  • Additional documentation gathered
  • Smart NC external review option identified
  • Timeline tracking established

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by individual circumstances and plan details. Always consult with your healthcare provider and insurance company for specific guidance regarding your situation. For additional help with insurance appeals, contact Smart NC at 1-855-408-1212 or visit the North Carolina Department of Insurance website.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.